GYRE (Gyre Therapeutics) Valuation Rank


GYRE Gyre Therapeutics Inc GYRE
39 GF Score
Price $6.23
GF Value $9.82
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Gyre Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Gyre Therapeutics Valuation Rank Related Terms

GYRE
39GF Score
Gyre Therapeutics Inc GYRE
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Gyre Therapeutics (GYRE) Overvalued in 2026?

Based on GuruFocus' analysis, Gyre Therapeutics stock appears to be undervalued. The current stock price of $6.23 is trading 36.6% below its estimated GF Value™ of $9.82. GuruFocus considers Gyre Therapeutics to be Significantly Undervalued.

Key valuation signals for GYRE:

  • Valuation Rank:
  • GF Value™: $9.82 vs. price of $6.23 (36.6% below fair value)
  • GF Score™: 39/100 with 2 warning signs

No single metric tells the full story. See the GYRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gyre Therapeutics Business Description

Other Exchanges L9S:Germany
Address 12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
39GF Score

Get the complete analysis for GYRE

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.23
Price
$9.82
GF Value